Across TCGA pan-cancer cohorts, DNAJC15 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DNAJC15 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DNAJC15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAJC15 expression acts as an unfavorable survival marker.
BLCA and UCEC are the cancer types where DNAJC15 Mutation most reproducibly stratifies survival.